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Background/aim: Treatment of hepatic hemangiomas is a controversial topic, and traditional treatment is surgical excision. Transcatheter
arterial embolisation (TAE) and transcatheter arterial chemoembolisation (TACE) have been reported as minimally invasive treatment
methods. To the best of our knowledge, there are no studies comparing use of TACE and TAE for hepatic hemangioma treatment. The
aim of the study is to compare symptom resolution, size reducing effects, and complications of TACE and TAE for the treatment of giant
hepatic hemangiomas.
Materials and methods: A total of 104 patients underwent TACE using bleomycin, and 108 patients underwent TAE. The patients were
followed-up for 2 year and follow-up images at 6 months, 12 months, and 24 months were acquired. Lesion volumes in both follow-up
images were calculated. The patients were examined for any possible procedure related complications as well as the status of their initial
symptoms.
Results: The shrinkage period was determined to have ended after 12. month in both groups. The results of the two-way mixed ANOVA
showed that there was significant main effect of procedure type (p ≤ 0.001) on hemangioma volumes. Similarly, there was a significant
interaction between procedure and time (p ≤ 0.001).
Conclusion: Both methods are effective in symptomatic relief in properly selected patients. However, TACE causes greater volume
reduction with less pain and, therefore, is the better endovascular treatment option.
Key words: Liver, hemangioma, angiography, bleomycin, embolization

1. Introduction
Hemangiomas are the most common primary tumors
of the liver, with a prevalence ranging from 3% up
to 20% being reported in the literature [1–3]. Most
lesions are asymptomatic and detected incidentally [1].
Lesions greater than 4 cm are called giant hemangiomas
in which case they might be symptomatic and, thus,
require treatment [1,2]. When and how to treat hepatic
hemangiomas is a controversial topic, with treatment
generally being considered only in cases of symptomatic
lesions, hemangiomas that are progressively growing
or at high risk of bleeding [3,4]. Abdominal pain or
discomfort and compression findings are the most
frequent indication for treatment [1–4]. Corticosteroids,
radiotherapy, cytotoxic agents, and surgery have
been used for treatment, with surgical resection
being the traditional treatment method [1,2,5,6–9].
Transcatheter arterial embolisation (TAE) is a blocking
vascularity method by a substance without biological

active substance. This procedure is the basic blocking
vascularity method via endovascular path. It has been
suggested as a less invasive alternative treatment that
can be used prior to surgery as well as by itself as the
primary treatment [1,2,10]. Similarly, transcatheter
arterial chemoembolisation (TACE) is another blocking
method. But, for this method, a biologically active
agent is used in addition to the embolization material.
Bleomycin, pingyangmycin, or ethanol has been
reported in the literature to treat the hemangioma of
liver [1,10–13]. Even though there are case series and
studies demonstrating potential utility of either method,
to the best of our knowledge, there are no studies in the
literature comparing the efficiency, rate of success and
complications of these minimally invasive treatment
modalities. Thus, the purpose of this retrospective study
was to evaluate and compare symptom improvement
and size reducing effects and complications of TACE and
TAE for the treatment of hepatic hemangiomas.
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2. Materials and methods
This was a retrospective study, approved by the Institutional
Review Board. Between 2002 and 2018, 104 patients (56
male and 48 female patients; mean age 49.5±10.8 years)
underwent TACE and 108 patients (78 male and 30 female
patients; mean age 50.6±12.8 years) underwent TAE.
The patients were referred to our department with
giant hepatic hemangiomas detected in the workup for
abdominal pain. Complete blood counts, hemostasis
parameters, kidney and liver function tests before the
procedure were unremarkable.
2.1. Procedure details
Until 2008, symptomatic patients with giant hemangiomas
were treated in our center with TAE. After this date, based
on reports of TACE in the literature, we started to treat
those patients with TACE using bleomycin.
Prior to both procedures, the patients were
premedicated with 1.2 mg/kg methylprednisolone, 50 mg
ranitidine, 50 mg tramadol, and 10 mg metoclopramide
right before embolisation.
2.2. Treatment
Embolization was performed by interventional radiologists
with at least 5 years of experience. Informed consent
was obtained from the patients in all cases. Under local
anesthesia, femoral artery access was obtained using an
18G Seldinger needle. Abdominal aorta was catheterized
with a 5F pigtail catheter (Imager, Boston Scientific,
USA, COOK Medical, USA and Cordis, USA) under the
guidance of a 0.035 inch J guide, and radiographs were
taken. Abdominal aorta, celiac artery (CA) and superior
mesenteric artery (SMA) outlet levels were detected. The
hepatic arterial system was mapped, the possible variations
were examined, and the nutrient artery of the existing
lesion in the liver was determined. Afterwards, radiographs
were taken with selectively catheterization of CA or SMA
(in case of replaced hepatic artery) with 5F renal catheter
(Imager, Boston Scientific, USA, COOK Medical, USA
and Cordis, USA). The feeder of the hemangioma was
superselectively catheterized with a 0.014inch microguideguided (Nitrex Guidewire, ev3, Micro Therapeutics, USA)
microcatheter (Prograte, Terumo, USA, HI-FLO System
Kit, Boston Scientific, USA, Rebar 027 Micro Catheter,
ev3, Micro Therapeutics, USA) , and embolization was
performed. For TAE, polyvinyl alcohol (PVA) particles
(355-500 contour, Boston Scientific, USA) were used as
embolizing agent. For TACE, combination of Lipiodol
(Guerbet, France) with bleomycin sulphate (Bleosin-s
ONKO-Koçsel, Turkey) was used as embolizing agent
at 2:1 ratio in 5 mL saline solution. The procedure was
terminated when as many sinusoids of the hemangioma as
possible were filled, as shown in Figure 1.
In the treatment of TAE, 2 vial PVA was used in 86 of
128 hemangiomas in 108 cases, 3 vials and 3 vials in 14
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Figure 1: Digital subtraction angiography image showing the
sinusoids of giant hemangioma filled with lipiodol-bleomycin
mixture.

patients. Second session embolization was required for 20
patients.
In TACE treatment, a 15 mL mixture was prepared by
diluting 10 mL of lipiodol and 15 mg of bleomycin vials with
5 mL of isotonic (at ratio 2:1). In cases where it was needed
more, this mixture was added in following proportions: 15
mL (15 mg belomycin) in 70 of 144 hemangiomas, 20 mL
(20 mg bleomycin) in 30, 25 mL (25 mg bleomycin) in 25
patients and 30 mL (30 mg bleomycin) in 19 patients. The
dose of 30 mg bleomycin per session was not exceeded.
Second session embolization was required in 14 cases.
All second session applications were performed in
cases where it was seen that sufficient reduction and
clinical benefit could not be achieved at the 12th month.
2.3. Postprocedure
After embolisation, all patients were hospitalised for 24
h. Their body temperature, blood pressure, and heart rate
were monitored at 4 h intervals. Their CBC was evaluated
twice at 12 h intervals, and LFTs were evaluated after
24 h. By the results of post embolizastion syndrome,
postprocedure abdominal pain was evaluated using the
numeric pain rating scale, with values going from 0 to
10 as the pain increases (McCaffery Pain scale). In cases
who had pain that required analgesics, in addition to
the routine follow-up measures described above, their
CBCs were checked, and they also underwent abdominal
ultrasonography to exclude hemorrhage.
2.4. Calculated tumor volume
Tumor volume was calculated by using the formula 0.5 ×
L × W × H ( L=the greatest length, W= the greatest width,
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H=the greatest depth or height) at dynamic and multiphase
contrast-enhanced computed tomography (CT) and
magnetic resonance imaging (MRI) images, which were
obtained before operation and at follow-up period.
2.5. Follow-up
The patients were followed-up for 2 year and followup images at 6 months, 12 months and 24 months were
acquired as shown in Figure 2A-B and 3A-B. The patients
were examined for any possible procedure related
complications as well as the status of their initial symptoms.
At the first year of follow-up, a second session of treatment
was performed in which the lesion’s longest diameter did
not fall below 4 cm or whose symptoms persisted. Other
patients were removed from follow-up.
2.6. Statistical analysis
Statistics Package for Social Sciences (SPSS) v21.0 was
used for statistical analysis. Student’s t test was used to
compare means. Data waere presented as mean±standard
deviation for variables suitable for normal distribution and
presented as median (minimum-maximum) for variables
not suitable for normal distribution. Two-factor ANOVA
was used to evaluate the interaction between procedure
type and time, and one-factor repeated-measures
analysis of variance (ANOVA) with the use of Bonferroni
adjustment for comparisons against the hemangioma
volumes prior to treatment. A p value < 0.05 was used
to assess the significance for all statistical analyses. The
results are presented as means ± SEMs.
3. Results
In the TACE group (n = 104), 14 patients (13.5%) had 2, 6
patients (5.8%) had 3, 2 patient (1.9%) had 4 and 2 patient
(1.9%) had 5 lesions; rest of the patients had one lesion for
a total of 144 hemangiomas. In the TAE group (n = 108),
16 patients (14.8%) had 2 lesions and 2 patient (1.9%) had
3 lesions; rest of the patients had one lesion for a total of

128 hemangiomas.
Mean lesion volume prior to treatment (considering
total volume of all lesions in patients with multiple
hemangiomas) was 294.48±22.81 cm3 (minimum 55.00,
maximum 3280.00) for TAE patients (Figure 2A) and
260.23±30.52 cm3 (minimum 37.00, maximum 3400.00)
for TACE patients (Figure 3A). The values were similar for
both groups (p = 0.526).
Following either TACE or TAE, follow-up images at 6
months demonstrated that the mean lesion volume was
183.48 ± 21.37 cm3 (minimum 25.00, maximum 1910.00)
in TACE group and 273.50 ± 22.36 cm3 (minimum 45.00,
maximum 2204.00) in TAE group.
In follow-up images at 12 months, mean lesion volume
was 211.24 ± 17.23 cm3 (minimum 40.00, maximum
775.00) in TAE (Figure 2B) group and 53.38 ± 6.16 cm3
(minimum 5.00, maximum 590.00) in TACE group
(Figure 3B).
In the 24th month follow-up, mean lesion volume
was 52.13±5.94 cm3 (minimum 5.00, maximum 580.00)
in TACE group and 208.48±17.06 cm3 (minimum 40.00,
maximum 770.00) in TAE group.
The shrinkage period was determined to have ended
after 12 month in both groups (Table). The results of the
two-way mixed ANOVA showed that there was significant
main effect of procedure type (p ≤ 0.001) on hemangioma
volumes. Similarly, there was a significant interaction
between procedure and time (p ≤ 0.001).
Findings related to lesion volumes and follow-up
results are presented in Table.
3.1. Complications
Following TAE, all patients had postembolization
syndrome consisting of abdominal pain, nausea, loss of
appetite, and low-grade fever. The most common symptom
was pain. According to Mccaffery pain scale, the average
score was 7.0 ± 0.8 (95% CI 6.7–7.2, minimum 4, maximum

Figure 2: A: Arterial phase CT image of a hepatic giant hemangioma before TAE treatment arrow shows the lesion.
B: Arterial phase CT image of a hepatic giant hemangioma 12 months after TAE treatment arrow shows the lesion.
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Figure 3: A: Arterial phase CT image of a hepatic giant hemangioma before TACE treantment. Arrows show the lesions.
B: Arterial phase CT image of a hepatic giant hemangioma 12 months after TACE treatment. Arrows show the lesions.
Table: Findings related to lesion volumes and follow-up results are presented.

Mean hemangioma volume over time by procedure type

Mean volume (cc)

400

300

TAE
200

100

0

TACE

Hemangioma volume prior Hemangioma volume at 6.Hemangioma volume at 12.Hemangioma volume at 24.
to treatment (cc)
month (cc)
month (cc)
month (cc)
Error Bars: 95% CI
Error Bars: +/- 2 SE

9, median 7) (Figure 4). The patients were managed with
mild analgesics. In 86 patients, the pain regressed in
24 h; however, 22 patients (20.4%) had persistent pain
because of which their hospitalization was extended to
48 h. Following 48 h, they, too, were discharged upon
resolution of their pain. 38 patients (35.2%) had low grade
fever (<38.0˚C) not requiring medication. Three patients
(5.6%) had temporary leucocytosis in the first week. Liver
function tests were elevated in 48 patients (44.4%) and
returned to less than twice the normal values or to normal
limits in all but 12. The 12 patients where LFTs remained
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elevated after 24 h were followed-up for another 24 h, and
their LFTs were within normal limits at the end of 48 h.
The most common complication seen after TACE was
also postembolization syndrome consisting of abdominal
pain, nausea, loss of appetite, and low grade fever of various
severity. Average numeric pain score was 5.0 ± 1.0 (95%
CI 4.7–5.2, minimum 3, maximum 7, median 5) (Figure
4). Fifteen patients (13.5%) had their postprocedural
hospitalization extended to 48 h because of pain. Twentyfour patients (23.1%) had low grade fever that did not
require any medication. Twenty-eight patients (26.9%)

ÖZGÜR and SİNDEL / Turk J Med Sci
Pain Scale
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Figure 4: Comparison of postembolization pain symptom of two procedures according
to the number of patients according to McCaffery pain scale (TAE n = 108, TACE n =
104 patients).

had elevated LFTs that decreased back to normal in 24
h. One patient presented with a biloma in their 1-week
control and was treated with percutaneous drainage
and antibiotics without any further complications. Two
patients had borderline kidney functions before the
procedure, and despite preventive measures before and
after TACE (consisting of N-acetyl cysteine and hydration)
had persisting creatinine increase at 2 months.
Postembolization pain, as graded according to the
numeric pain scale, was less in the TACE group than the
patients who underwent TAE (p < 0.001). The incidence
of fever and LFT elevation were similar in the two groups
(p = 0.358 and p = 0.060, respectively). Mean duration of
postprocedural hospitalization was shorter in the TACE
group (p = 0.27) and 48 h of hospitalization was more
common in TAE group (p = 0.27).
There was no life-threatening complications or longterm problems (except for the patient with decreased renal
function) caused by the procedures.
3.2. Resolution of symptoms
The procedures provided symptomatic relief in an
overwhelming majority of patients. The symptoms
were not resolved in 8 TACE patients, with two patients
describing a similar amount of abdominal pain, one patient
complaining of a decreased yet still persistent pain and
one patient presenting with an increased amount of pain.
It is interesting to note that in all 8 patients, lesion volume
had decreased almost 4-fold. Therefore, in these cases, the
initial abdominal pain was retrospectively considered not
to have been caused by hepatic hemangiomas despite the
lack of any other potential causes found during the workup
for abdominal pain.
4. Discussion
First reports of TAE to treat hepatic hemangiomas come
from Stanley et al. in 1983 who reported 2 infants with

infantile hepatic hemangiomas treated with TAE using
PVA, with shrinkage of lesions in both cases and from
Allison et al. in 1985, who reported one patient with
hemangioma who underwent TAE to relieve local pain
and decrease risk of bleeding from rupture [14, 15]. TAE
of a ruptured giant hemangioma prior to surgery was first
reported in 1991 by Yamamoto et al [3,16]. Since then, in
adults, TAE has been used to treat diffuse hemangiomatosis
and symptomatic hemangiomas [4]. Several cases have
been reported where TAE of ruptured giant hemangiomas
prior to emergency surgery have been performed [17,18].
TAE has also been used to treat Kasabach–Merritt
syndrome, following which coagulopathy is reported to
be quickly reversed [19,20]. There are also cases where
such embolization has been performed in nonruptured
hemangiomas before elective surgery [21,22].
Some recent studies demonstrate TAE can be effective
in treatment of symptomatic hemangiomas or lesions at
risk of rupture [4]. Srivastava et al reported eight patients
treated with TAE, where seven patients had complete
resolution of symptoms at 9 months, and one patient had
partial relief and then underwent surgery [4]. Firouznia
reported 20 patients treated with PVA particles who
had statistically significant reduction in lesion size and
decrease in symptoms [23]. Althaus et al. reported a
29-year-old patient applying with right upper quadrant
pain and revealed to have 2 giant hemangiomas, which
were treated with TAE using PVL. The patient reported
only minimal intermittent RUQ discomfort and was
otherwise asymptomatic 2 years after the procedure [24].
Deutsch et al. reported 3 cases treated with TAE with
resolution of symptoms and no significant complications
[25]. The most common side effects are pain, pyrexia,
leukocytosis, and nausea [4]. Serious complications are
rare [4, 14]. There has been a reported case with necrosis
of hemangioma followed by abscess formation [26]. Death
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caused by embolization of gallbladder, kidneys, and lungs
with gelfoam particles has also been described [27].
Bleomycin is an agent commonly used to treat vascular
anomalies [28]. It is a cycle-nonspecific cytotoxic agent
that degrades DNA through direct mechanisms and
also acts as an angiosclerotic agent, gradually inducing
a nonspecific inflammatory response around the tumor
as well as in the portal area [29]. Iodinated oil exhibits a
synergistic effect. TACE with bleomycin-iodinated oil
mixture (BIO) results in gradual, progressive destruction
of endothelia and elimination of the pathologic vascular
bed [29]. It is this quality that makes bleomycin potentially
useful for treatment of hepatic hemangiomas.
Studies reporting use of TACE for hemangioma
treatment are fewer in number. Interestingly, there have
been cases reported where systemic use of bleomycin
for cancer treatment caused a decrease in size of hepatic
hemangiomas [28,30,31]. Bozkaya et al. reported 32
lesions in 26 patients treated with bleomycin. There
was statistically significant reduction in size of lesions
with symptomatic improvement. One of their cases had
ischemic cholecystitis, otherwise there were no procedure
related complications [2]. Chinese researchers reported
several series using pingyangmycin, an agent similar to
blemoycin. Sun et al. treated 27 patients using lipiodol
mixed with pingyangmycin and reported reduction in
size of lesions. [8]. Another study treated 98 patients
using pingyangmycin-lipiodol emulsion with statistically
significant reduction in lesion size and resolution of
symptoms in all symptomatic patients [9]. Li et al.
reported 836 patients treated with pingyangmycinlipiodol mixture. Success rate as measured by resolution of
symptoms was 100%. [7]. Following TACE with bleomycin
or pingyangmycin, mild postembolization syndrome
has been reported. TACE with BIO can cause acute liver
failure, hepatic infarction, liver abscess, intrahepatic
biloma, intrahepatic aneurysms, hepatic artery perforation
or rupture, splenic infarction, cholecystitis, and sclerosing
cholangitis [7,29]. However, most complications have
been reported as case reports or cases in larger series and
seem to be the exception rather than rule. Overwhelming
majority of the patients reported in the above-mentioned
studies did not have major complications.
Firouznia and friends found that the average diameter
of tumors was 97.00 mm (range: 25-200 SD: 47.85) and
88.95 mm (range: 23-195 SD: 43.27) before and after

embolization, respectively [23]. In our study, mean lesion
volume prior to treatment was 294.48 ± 22.81 cm3 for TAE
patients. In follow-up images at 12 months mean lesion
volume was 211.24 ± 17.23 cm3 in TAE group. Results are
similar with each other.
Bozkaya and friends found that the mean volume of the
haemangiomas was 446.28 ± 88 cm3 (range 3.39–1559 cm3)
before intervention and 244.43 ± 54.38 cm3 (range 94–
967 cm3) after intervention. In our study, mean lesion
volume prior to treatment was 260.23 ± 30.52 cm3 and in
follow-up images at 12 months, mean lesion volume was
53.38 ± 6.16 cm3 [2]. Statistically significant reduction in
size was similar in both studies.
In our study, one patient presented with a biloma in
their 1-week control and was treated with percutaneous
drainage and antibiotics without any further complications.
In a study of 920 patients, 35 patients developed biloma,
who underwent surgical hepatectomy following drainage.
Biloma can develop iatrogenic, traumatic, or spontaneous.
The development of biloma in the field of embolization
develops due to malnutrition and infarction related to the
biller tract [32].
There are several limitations of our study. First of all,
the study is a retrospective study. Abdominal pain, which
is the most important symptom of hemangiomas, could
not be evaluated objectively before and after the procedure
but could only be examined in terms of clinical benefit. In
addition, the treatment response cannot be correlated with
the dose of bleomycin used in the TACE procedure. It is
thought that correlation of lesion volume and bleomycin
dose may provide additional information in future
prospective studies.
In conclusion, due to high rates of symptomatic relief
and lack of major complications, both TACE and TAE are
effective treatment modalities for hepatic hemangiomas in
properly selected patients. To the best of our knowledge,
this study is the first to compare the two methods’
efficiency in symptom resolution, incidence and severity of
complications, and 2-year follow-up results. According to
our findings, TACE using bleomycin causes a significantly
greater reduction in lesion volume, also having milder and
better tolerated postembolization abdominal pain and
resulting in shorter hospitalization after the procedure.
When minimally invasive endovascular treatment of giant
hepatic hemangiomas is considered, TACE should be
preferred over TAE.
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